Dr. Christian Kilger

  • Dipl. Biol. Univ., Ludwig-Maximilians Universität München
  • Dr. rer. nat., Ludwig-Maximilians Universität München
  • Patentanwalt
  • European Patent and Trademark Attorney

Dr. Christian Kilger was born in the United States and grew up in both Germany and the U.S. After studying genetics and biochemistry at the Ludwig-Maximilian’s University of Munich Germany he completed his Dipl. Biol. and Dr. rer. nat. degree in the laboratory of Prof. Svante Pääbo, the recipient of the Nobel Prize in Physiology and Medicine in 2022. Dr. Kilger’s work included research on ancient DNA projects – Molecular Genetic Analyses of the Tyrolean Ice Man, SCIENCE, 17 Jun 1994, Vol 264 – but mostly he focused on the development of novel nucleic acid amplification and sequencing techniques. As a Postdoc at the Max-Planck Institute for Evolutionary Genetics, Dr. Kilger was a frequent lecturer, also at the European Molecular Biological Laboratory teaching DNA sequencing techniques. Prof. Dr. h.c. Svante Pääbo who was his mentor as scientist received the Nobel Prize in Medicine and Physiology in 2022 for his ancient DNA work and the elucidation of the human evolution.

In 1997 Dr. Kilger joined LION bioscience AG a NASDAQ traded biotech company, where he was responsible for all global IP matters during its initial public offering on the German Stock exchange and the NASDAQ in the USA. Christian Kilgger went on to study law in Hagen, and became both European and German Patent Attorney. He is also registered as European Trademark Attorney.

Dr. Christian Kilger founded CH KILGER Anwaltspartnerschaft with its main office in Berlin, Germany and offices in Munich as well as Buenos Aires, Argentina after some years at both the IP law firms Boehmert & Boehmert and Vossius & Partner.

Dr. Kilger has represented numerous Biotech, Pharmaceutical, Diagnostic, Food/Beverage clients in complex opposition and patent infringement proceedings. Dr. Kilger is the author of numerous articles relating to the patenting of biotechnological inventions and frequently lectures in this field. He has served as an advisor to the State of Berlin, the World Intellectual Property Organization, the European Patent Office and the German Federal Ministry of Research on various IP issues. Dr. Kilger has repeatedly been mentioned in the Legal 500 and in JUVE. In 2013 Dr. Kilger received the International Client Choice Award in Intellectual Property Healthcare & Life Sciences.

  


Exemplary opposition, FTO, prosecution and patent infringement proceedings:

  • EP-B1 1 530 578 QIAGEN GmbH ./. ILLUMINA (USA), opposition and patent infringement suit;
  • EP-B1 1 638 704 Big Bell Solar ./. ECOTEC GmbH and ECONX (NL), representing alleged infringer in patent infringement suit and nullity action;
  • DE 196 55 282 represented alleged infringer in patent infringement suit and nullity action to the Germen Federal Supreme Court;
  • EP-B1 0 711 179 IMCORE ./. ACUSPHERE represented IMCORE in opposition;
  • EP-B1 0 810 030 QIAGEN GmbH ./. APPLERA Corp. USA, opposition and patent infringement suit;
  • Acquisition of DIAGENE by QIAGEN (HPv testing) for close to a billion USD; Due Diligence on behalf of QIAGEN;
  • STAT-Dx (multiplex PCR diagnostics) patent counsel until acquired for about 200 Mio USD;
  • EngMAB (anti-CD3 bi-specific antibodies) patent counsel until acquired for about 600 Mio USD by Cellgene;
  • WO2008118356 (antibody – alpha 4-integrin inhibitor) global patent prosecution on behalf of BIOGEN IDEC and UCB;
  • EP-B1 0 810 030 CLEMENS GmbH and PEQLAB GmbH ./. APPLERA patent infringement suit and opposition;

Exemplary Opposition proceedings before the EPO:

  • EP-B1 2 155 783 (AMGEN USA), CD3-epsilon binding domain, multiple opponents, Chugai, Roche, Pfizer, Affimed,
  • EngMAB, Janssen Biotech, Genmab;
  • EP-B1 0 639 228 (Baylor College), STR repeats in human identification, STRAWMAN;
  • EP-B1 0 960 207 (Promega Corp. USA), CODIS code in human identification, represented QIAGEN GmbH;
  • EP-B1 1 463 839 B1 (Norchip SA), HPv detection of 16, 18, 31, 33 and 45, represented QIAGEN GmbH;
  • EP-B1 1 913 157 (Hoffman La Roche), KRAS and EGFR for prediction of patient response to EGFR inhibitor, multiple opponents, Ely Lilly, Merck
  • USA, represented QIAGEN Manchester;
  • EP-B1 2 289 345 (Hofmeister KG), Cheese production, represented HOCHLAND SE
  • EP-B1 2 619 322 (Life Technologies), SE33 mutations impacting genotype concordance, represented QIAGEN GmbH
  • EP-B1 1 135 530 (Life Technologies), CODIS II, represented QIAGEN GmbH
  • EP-B1 2 394 617 (Paul Hartmann AG), Biomatrix with collagen, represented MEDSKIN Solutions Dr. Suwelack AG;
  • EP-B1 814 982 (Oncolytics), Improved viral Purification Methods, represented JANSSEN vaccines NL;
  • EP-B1 2 940 044 (ABBvIE), Anti TNF alpha AB/40 EOW for Rheum Arth. plus Methotrexate (HUMIRA), multiple opponents including HEXAL AG,
  • Biogen Inc., Mylan, AMGEN (USA), PAJARO, Pfizer and Samsung, acting as STRAWMAN;
  • EP-B1 2 325 304 (Epicentre), Polymerases in Next Generation Sequencing, STRAWMAN;
  • EP-B1 1 910 559 (Illumina, USA), Next Generation Sequencing, STRAWMAN;

Exemplary list of clients:
Max-Planck-Institutes (DE)
Fraunhofer Institutes (DE)
CONICET (ARG)
Johnson & Johnson (USA)
Genentech (USA)
Chugai
Biogen Idec
Regeneron
ALvOTECH (Iceland)
Mylan (USA)
Schering AG (Berlin)
Hoffman la Roche (CH)
EngMAB
QIAGEN GmbH
QIAGEN Manchester
QIAGEN (USA)
Janssen vaccines (NL)
Takeda (Japan)
Charité (Berlin)
FEDEX (USA)
The Johns Hopkins University
Vanderbilt University
TEvA (Israel)
AMSILK AG
Celgene Corp. (USA)
DSM (NL)
LONZA Inc. (USA)
LONZA (CH)

Dr. Christian Kilger
kilger@chkilger.com
t +49 30 886 20 07 – 0


AREAS OF FOCUS

  • Opposition and infringement proceedings
    Pharmaceuticals (biomolecule based therapeutics, Abs of all kinds)
  • Diagnostics (nucleic acid and protein based diagnostics)
  • Cosmetics (biomolcule medical devices, hyaloronic acid technology)
  • Food and beverages
  • Due Diligence & Licensing/M&A